DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

Duke COI Reporting is based on the previous year and anticipated relationships for the coming year. Please report current and anticipated information for the calendar year (January through December) 2017. For audit purposes, please keep conflict of interest/financial records for three years after the conclusion of the award.

How to Use This Form:

- 1) Save the document on your drive.
- 2) Enter the Year (e.g. 2016), your Name, Title and Address in the appropriate fields.
- 3) Make sure you save your version on your drive.
- 4) Then Click on "File", click "Protect Document", in the drop-down menu click "Restrict Editing". In the column to the right at the bottom click "unprotect".
- 5) Click on the appropriate checkboxes.
- 6) Save your updated version on your drive
- 7) Send an email to DCRI Communications (DCRIExternalWebsite@dm.duke.edu) with your COI attached for posting on our DCRI website.

Editing the Document (Necessary only when you have to add companies not on the form):

- 1) Scroll down to the last page to the blank rows and enter the company name(s) on the company field(s).
- 2) Enter new information.
- 3) Click on the appropriate checkboxes on your new listing and save.
- Make sure you save your version on your drive.

Column Explanations:

- (1) Funding is provided for my effort in research grants or contracts for multi-center projects in which I serve as either the Chairman, Co-Chairman, Executive or Steering Committee member or I am involved as a DCRI faculty leader for specific aspects in a project. A check in this column denotes that I am involved in such a research contract. Payments for the work performed for these contracts are made to the University. A portion of my salary as a faculty member, representative of % effort on the project, is supported by these funds.
- (2) A research grant from this company supports the expenses associated with projects in the DUHS that are under my direction.
- (3) I provide educational activities or deliver occasional lectures that generate revenue from this company. All revenues from these activities are paid to the University. None of it is taken for personal income. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- (4) I receive personal income outside of my University salary for consulting or other services (Including CME) from this company. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- (5) I receive personal income outside of my University salary for consulting or other non-CME services from this company. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- **(6)** I personally receive royalties in excess of \$5,000 per year from this company.
- (7) I, or an immediate member of my family, have equity (with shareholder voting privileges) in this company of either > \$5,000 or > 1%.

^{***}If you have no conflict to report please check the box at the end of the list.

DCRI COMMERCIAL RELATIONSHIPS TRACKING FORM

Year:	2017	
Name:	Jennifer Green, MD	
Title:	Associate Professor of Medicine	
Address:	North Pavilion room 7039	

Please complete the applicable rows in the following table. Monetary amounts are on an annual basis.

Company:	(1) A Research Grant or Contract from this Company Partially Supports My	(2) A Research Grant or Contract from this Company Supports My Research Projects	(3) Educational Activities or Lectures for this Company Generates Revenue for Duke			(4) Consulting or Other Services (Including CME) for this Company Generates Personal Income			Otl Ser Comp	Consultiner non- vices for cany Ger sonal Ind	CME r this nerates	(6) I Receive Significant Personal Royalties from this	(7) I Have Equity in this Company	
	University Salary		<\$5K	\$5K- \$25K	>\$25K	<\$5K	\$5K- \$25K	>\$25K	<\$5K	\$5K- \$25K	>\$25K	Company	<\$5 K	>\$5K/1%
Abbott Laboratories														
Abiomed														
Acerta Pharma														
Achillion Pharmaceuticals														
Acorda Therapeutics, Inc														
Aires Pharmaceuticals														
Akili Interactive Labs														
Alcobra														
Amgen, Inc.														
Amylin Pharmaceuticals, Inc.														
ARCA Biopharma														
Ardea Biosciences, Inc.														
Armetheon Inc														

AstraZeneca	\boxtimes							
Atentiv Inc								
Baseline Study LLC								
Baxalta								
Bayer Corporation US (Bayer AG/Bayer in Japan – subsidiaries)								
Beckman Research Institiute								
Bellerophon Therapeutics								
Biogen								
Biogen Idec In								
Biomarin								
Biosensors International Group Ltd								
BioStealth Inc								
Boehringer Ingelheim								
Boston Scientific Corporation								
Bristol Myers Squibb								
Burroughs Welcome Fund								
Cardio3 Bioscience								
CardioDx, Inc.								
Cardiovascular Systems, Inc.								
Cempra Pharmaceuticals, Inc.								
Cerenova, LLC								
CPC Clinical Research								

CSL Group							
CSL Limited							
Cubist Pharmaceuticals							
Daiichi Sankyo Co. Limited							
Deloitte Consulting LLP							
Dr. Reddy's Laboratories LTD							
Duke Clinical Research Institute							
Duke Neurology Imaging Lab							
Durata Therapeutics							
Edwards Lifesciences							
Elesvier							
Eli Lilly & Company							
Evalve, Inc							
Exelixis, Inc.							
F Hoffmann-La Roche Ltd							
Ferring Pharmaceuticals							
Genentech							
General Electric Company							
General Electric Healthcare							
Genetic Alliance							
Genzyme Corporation							
Gilead Sciences, Inc.							
Glaxo SmithKline (GSK)							

Grifols							
Harvard Pilgrim Health Care							
HeartFlow							
Hologic, Inc.							
Humacyte, Inc							
Immuron Ltd							
Janssen Pharmaceutica Products, L.P.							
Janssen Research and Development, LLC							
Janssen Scientific Affairs, LLB							
Johnson & Johnson							
Johnson & Johnson Pharmaceutical Research & Development							
LadeRX							
Luitpold Pharmaceuticals, Inc.							
MAQUET Cardiovascular LLC (formerly Boston Scientific Cardiac & Vascular)							
Marinus Pharmaceuticals Inc							
Medical Education Solutions Group							
MedImmune Inc							
Medscape, LLC							
Medtronic PLC							

Medtronic Vascular, Inc. (formerly Medtronic AVE)							
Merck & Co., Inc							
Merck Sharp & Dohme I.A. Corporation							
MyoKardia Inc							
Novartis Consumer Health Inc							
Novartis Pharmaceutical Company							
Novavax Inc							
Ophthotech Corporation							
OrbusNeich							
Otsuka America Pharmaceutical							
Oxygen Biotherapeutics (Formerly SBI)							
Pfizer							
Popluation Health Research Institute							
Portola Pharmaceutical							
Procyrion Inc							
Reflexion Health							
Regeneron Pharmaceuticals, Inc.							
Research Triangle Institute							
ResMed							
RespireRX Pharmaceuticals							

Roche Diagnostics							
Roche Diagnostics Corp							
Roche Group							
Sanofi-Aventis							
Shionogi Inc							
Society of Thoracic Surgeons							
Stealth Peptides							
Summit							
Swedish Orphan Biovitrum AB							
Tacere Therapeutics							
Taiwanj Pharmaceuticals Company Ltg							
The Medicines Company							
Theravance Biopharma							
Thrombosis Research Institute							
Tokalas Inc							
University of Michigan							
Verily Life Sciences							
Zimmer Biomet Holdings Inc							
Intarcia							
NovoNordisk					\boxtimes		

[☐] No Conflicts to report

Column Explanations:

- (1) Funding is provided for my effort in research grants or contracts for multi-center projects in which I serve as either the Chairman, Co-Chairman, Executive or Steering Committee member or I am involved as a DCRI faculty leader for specific aspects in a project. A check in this column denotes that I am involved in such a research contract. Payments for the work performed for these contracts are made to the University. A portion of my salary as a faculty member, representative of % effort on the project, is supported by these funds.
- (2) A research grant from this company supports the expenses associated with projects in the DUHS that are under my direction.
- (3) I provide educational activities or deliver occasional lectures that generate revenue from this company. All revenues from these activities are paid to the University. None of it is taken for personal income. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- (4) I receive personal income outside of my University salary for consulting or other services (Including CME) from this company. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- (5) I receive personal income outside of my University salary for consulting or other non-CME services from this company. The three columns represent annual payments of more than \$5,000, between \$5,000 and \$25,000, and in excess of \$25,000 per year from this company.
- **(6)** I personally receive royalties in excess of \$5,000 per year from this company.
- (7) I, or an immediate member of my family, have equity (with shareholder voting privileges) in this company of either > \$5,000 or > 1%.